Speakers 2015

    • Presentation

    • How to optimize current therapy of G1 patients (chairman)

    • Future therapeutic strategies with direct acting antivirals (chairman)

    View more
  • ALAHDAB Yesim

    Turkey

      Presentation

    • W2

    View more
  • ARROYO Vicente

    Spain

      Presentation

    • Acute-on-chronic liver failure is a new clinical entity

    View more
  • ASSELAH Tarik

    France

      Presentation

    • State of the art lecture (chairman)

    • INF-free therapy in naïve patients

    • Take home messages

    • State of the art lecture (chairman)

    • How to optimize treatment in G4 patients? (chairman)

    • Take home message

    View more
  • BEDOSSA Pierre

    France

      Presentation

    • Staging of fibrosis: liver biopsy or indirect markers? (chairman)

    • Cirrhosis reversibility: who and why?

    View more
  • BENAZZOUZ Mustapha

    Morocco

      Presentation

    • Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)

    View more
  • BENHAMOU Yves

    France

      Presentation

    • Yes

    • Future therapeutic strategies with direct acting antivirals (chairman)

    View more
  • BERG Thomas

    Germany

      Presentation

    • Shortened therapy with IFN-based therapy

    View more
    • Presentation

    • Genotype 2, what’s new?

    View more
  • BOYER Nathalie

    France

      Presentation

    • Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)

    View more
  • BRONOWICKI Jean-Pierre

    France

      Presentation

    • Traitements des patients rechuteurs et non répondeurs (French speaking lunch workshop) (chairman)

    View more
    • Presentation

    • Patients with comorbidities

    View more
  • BUTI Maria

    Spain

      Presentation

    • Special populations (chairman)

    View more
  • CADRANEL Jean-François

    France

      Presentation

    • Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)

    View more
  • CALVARUSO Vincenza

    Italy

      Presentation

    • Quantification of fibrosis and cirrhosis outcomes

    View more
  • CASTERA Laurent

    France

      Presentation

    • The control of HBV related liver disease (chairman)

    View more
  • COLOMBO Massimo

    Italy

      Presentation

    • Can we predict HCC in chronic viral hepatitis?

    • How to improve access to therapy? (chairman)

    • Management of hepatocellular carcinoma in 2015

    View more
  • CRAXI Antonio

    Italy

      Presentation

    • Treatment of hepatitis C today and tomorrow

    • How to optimize treatment in G1 naive patients? (chairman)

    View more
  • DE LEDINGHEN Victor

    France

      Presentation

    • Staging of fibrosis: liver biopsy or indirect markers? (chairman)

    View more
  • DEBZI Nabil

    Algeria

      Presentation

    • Comment optimiser le traitement des malades naïfs ? (French speaking lunch workshop) (chairman)

    View more
  • DHUMEAUX Daniel

    France

      Presentation

    • Comment optimiser le traitement des malades naïfs ? (French speaking lunch workshop) (chairman)

    View more
  • DI BISCEGLIE Adrian

    USA

      Presentation

    • End-stage liver disease is a multifaceted condition (chairman)

    View more
  • DURAND François

    France

      Presentation

    • Special populations (chairman)

    View more
  • DUSHEIKO Geoffrey

    UK

      Presentation

    • Antiviral treatment in HCV cirrhotic patients on waiting list

    • Hepatitis C: new challenges in the era of DAAs (chairman)

    View more
  • ESMAT Gamal

    Egypt

      Presentation

    • How to optimize treatment in G4 patients? (chairman)

    View more
  • ESTEBAN Rafael

    Spain

      Presentation

    • First line therapy of hepatitis B: interferon or analogues? (chairman)

    View more
  • ESTRABAUD Emilie

    France

      Presentation

    • HCV eradication with DAAs? (chairman)

    View more
  • FERENCI Peter

    Austria

      Presentation

    • How to manage relapsers and non-responders to PEG IFN + RBV therapy (chairman)

    View more
  • FERRARI Carlo

    Italy

      Presentation

    • HBV and the immune response

    View more
  • FLISIAK Robert

    Poland

      Presentation

    • Access to treatment and disease burden

    View more
  • FOSTER Graham

    UK

      Presentation

    • Why genotype 3 is difficult to cure?

    View more
    • Presentation

    • How to improve access to therapy? (chairman)

    • HCV eradication with DAAs? (chairman)

    View more
    • Presentation

    • Optimal therapy of chronic hepatitis B (chairman)

    View more
  • GOVAERE Olivier

    Belgium

      Presentation

    • Hepatic progenitor cells in chronic liver diseases

    View more
  • HALFON Philippe

    France

      Presentation

    • Clinical applications of HBsAg quantification (chairman)

    View more
  • HEZODE Christophe

    France

      Presentation

    • Traitements des patients rechuteurs et non répondeurs (French speaking lunch workshop) (chairman)

    View more
  • HORBAN Andrzej

    Poland

      Presentation

    • How to manage relapsers and non-responders to PEG IFN + RBV therapy (chairman)

    View more
  • ISAKOV Vasily

    Russia

      Presentation

    • Workshop 1: Non invasive methods for fibrosis in the management of cirrhosis (chairman)

    View more
    • Presentation

    • New therapeutic strategies (chairman)

    View more
  • JALAN Rajiv

    UK

      Presentation

    • Treatment of HCV cirrhosis and transplanted patients (chairman)

    View more
    • Presentation

    • PEG IFN based therapy with 2nd wave DAAs

    • Triple therapy with telaprevir or boceprevir: management of side effects (chairman)

    View more
  • JIA Jidong

    China

      Presentation

    • Optimal therapy of chronic hepatitis B (chairman)

    View more
  • KAO Jia-Horng

    Taiwan

      Presentation

    • The long term impact of treatment on the outcome of liver disease (chairman)

    • What have we learned from HBV clinical cohorts?

    View more
  • KARAGINANNAKIS Dimitrios

    Greece

      Presentation

    • Cardiomyopathy in cirrhosis

    View more
  • KILANI Badreddine

    Tunisia

      Presentation

    • Traitements des patients rechuteurs et non répondeurs (French speaking lunch workshop) (chairman)

    View more
  • KOUCHNER Bernard

    France

      Presentation

    • Hepatitis C: A public health priority

    View more
  • LAMPERTICO Pietro

    Italy

      Presentation

    • How do I treat my HBeAg-negative patients?

    View more
  • LARSSON Simon

    Sweden

      Presentation

    • Workshop 3: The role of Pegylated IFN in HBV therapy (chairman)

    • W3

    View more
  • LEQUOY Marie

    France

      Presentation

    • Somatostatin receptors and HCC

    View more
  • LEROY Vincent

    France

      Presentation

    • Traitements des patients rechuteurs et non répondeurs (French speaking lunch workshop) (chairman)

    View more
  • LEVRERO Massimo

    France

      Presentation

    • Short presentations (chairman)

    • HCV eradication with DAAs? (chairman)

    View more
    • Presentation

    • How to optimize current therapy of non G1 patients (chairman)

    View more
  • LOANNIDOU Panagiota

    Greece

      Presentation

    • W4

    View more
  • MANNS Michael

    Germany

      Presentation

    • New therapeutic strategies (chairman)

    View more
  • MARCELLIN Patrick

    France

      Presentation

    • Introduction

    • Restitution of workshops (chairman)

    • Awards and Conclusion

    • Introduction: Treatment of hepatitis C: towards the eradication?

    • How to improve access to therapy? (chairman)

    • Conclusion

    • Introduction: is HBV controlled?

    • State of the art lecture and Award (chairman)

    • Conclusion

    View more
  • MARTINOT-PEIGNOUX Michelle

    France

      Presentation

    • Clinical applications of HBsAg quantification (chairman)

    • HBsAg quantification to manage patients

    View more
  • MATHURIN Philippe

    France

      Presentation

    • Comment optimiser le traitement des malades naïfs ? (French speaking lunch workshop) (chairman)

    View more
  • MEHTA Gautam

    UK

      Presentation

    • W2

    View more
  • MINDRUT Eugenia

    Romania

      Presentation

    • W4

    View more
  • MOREAU Richard

    France

      Presentation

    • End-stage liver disease is a multifaceted condition (chairman)

    View more
  • MORENO Christophe

    Belgium

      Presentation

    • Controversies in the management of cirrhosis (chairman)

    • Workshop 2: Management of acute alcoholic hepatitis (chairman)

    View more
  • MOROZOV Sergey

    Russia

      Presentation

    • Workshop 3: The role of Pegylated IFN in HBV therapy (chairman)

    • W3

    View more
  • NEGRO Francesco

    Switzerland

      Presentation

    • Short presentations (chairman)

    View more
    • Presentation

    • INF-free therapy in experienced patients

    View more
  • OUZAN Denis

    France

      Presentation

    • Interferon ou analogue ? (French speaking lunch workshop) (chairman)

    View more
  • PAIS Raluca

    France

      Presentation

    • How to optimize treatment in G1 naive patients? (chairman)

    View more
  • PAPATHEODORIDIS Georgios

    Greece

      Presentation

    • How do I treat my HBeAg-positive patients?

    View more
  • PARANA Raymundo

    Brazil

      Presentation

    View more
  • PARFIENUIK-KOWERDA Anna

    Poland

      Presentation

    • Apoptosis in chronic hepatitis C

    View more
  • PECK RADOSAVLJEVIC Markus

    Austria

      Presentation

    • Triple therapy with telaprevir or boceprevir: management of side effects (chairman)

    View more
  • PERALVAREZ Manuel Rodriguez

    Spain

      Presentation

    • W1

    View more
  • PETERSEN Jorg

    Germany

      Presentation

    • HBV: perspectives for treatment

    View more
  • POL Stanislas

    France

      Presentation

    • Workshop 4: Severe liver diseases in HIV patients (chairman)

    • Hepatitis C: new challenges in the era of DAAs (chairman)

    • How to optimize current therapy of G1 patients (chairman)

    View more
  • POPESCU Adriana

    Romania

      Presentation

    • Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)

    View more
  • PUNETE SANCHEZ Ángela

    Spain

      Presentation

    • Beta blockers in cirrhosis

    View more
  • RADASAN Andreea

    Romania

      Presentation

    • W1

    View more
  • RATZIU Vlad

    France

      Presentation

    • How to optimize treatment in G1 naive patients? (chairman)

    View more
  • ROCKSTROH Juergen

    Germany

      Presentation

    • HIV-HCV coinfections (chairman)

    • HIV co-infected patients

    View more
  • SAMUEL Didier

    France

      Presentation

    • Controversies in the management of cirrhosis (chairman)

    • Workshop 1: Non invasive methods for fibrosis in the management of cirrhosis (chairman)

    • Treatment of HCV cirrhosis and transplanted patients (chairman)

    • DAAs and transplant patients

    View more
  • SCHIFF Eugene

    USA

      Presentation

    • Controversy: Cure of HCV-related liver disease? (chairman)

    • Viral hepatitis: the past and the future

    View more
  • SERFATY Lawrence

    France

      Presentation

    • Workshop 2: Management of acute alcoholic hepatitis (chairman)

    • Patients monitoring after SVR

    • Awards and Conclusion

    • Predictors of response to IFN-based therapy

    View more
  • SHIFFMAN Mitchell

    USA

      Presentation

    • No

    View more
  • SOGNI Philippe

    France

      Presentation

    • Clinical applications of HBsAg quantification (chairman)

    View more
  • STREINU-CERCEL Anca

    Romania

      Presentation

    • How to optimize treatment in G1 naive patients? (chairman)

    View more
  • SULKOWSKI Mark

    USA

      Presentation

    • HIV-HCV coinfections (chairman)

    View more
  • TOMASIEWICZ Krzysztof

    Poland

      Presentation

    • Antiviral treatment in HCV cirrhotic patients on waiting list

    View more
  • TOZUN Nurdan

    Turkey

      Presentation

    • Workshop 4: Severe liver diseases in HIV patients (chairman)

    • The long term impact of treatment on the outcome of liver disease (chairman)

    View more
  • TREPO Christian

    France

      Presentation

    • Interferon ou analogue ? (French speaking lunch workshop) (chairman)

    View more
  • TREPO Eric

    France

      Presentation

    • Beta blockers in cirrhosis

    View more
  • URBANEK Petr

    Czech Republic

      Presentation

    • Triple therapy with telaprevir or boceprevir: management of side effects (chairman)

    View more
  • VALLA Dominique

    France

      Presentation

    • Treatment of HCV cirrhosis and transplanted patients (chairman)

    • The coagulation system in end-stage liver disease

    View more
  • VOICULESCU Mihai

    Romania

      Presentation

    • Restitution of workshops (chairman)

    • Comment optimiser le traitement des malades naïfs ? (French speaking lunch workshop) (chairman)

    View more
  • WAKED Imam

    Egypt

      Presentation

    • Genotype 4, finally cured?

    View more
  • WEILAND Ola

    Sweden

      Presentation

    • Resistance

    View more
  • YURDAYDIN Cihan

    Turkey

      Presentation

    • First line therapy of hepatitis B: interferon or analogues? (chairman)

    View more
  • ZARSKI Jean-Pierre

    France

      Presentation

    • Interferon ou analogue ? (French speaking lunch workshop) (chairman)

    View more
  • ZEUZEM Stefan

    Germany

      Presentation

    • How to optimize current therapy of non G1 patients (chairman)

    View more
  • ZHDANOV Konstantin

    Russia

      Presentation

    • How to manage relapsers and non-responders to PEG IFN + RBV therapy (chairman)

    View more
  • ZOULIM Fabien

    France

      Presentation

    • The control of HBV related liver disease (chairman)

    View more